Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/7/2025

Evolocumab Evidence and Guidelines for Lipid Management

Primary Prevention Evidence Gap

  • No primary prevention trials with evolocumab have been completed or published. 1, 2

  • In primary prevention populations (except familial hypercholesterolemia), the number needed to treat would be prohibitively high. 1

Primary Prevention Guidelines

  • Moderate-intensity statin therapy is recommended for patients ≥40 years with diabetes. 3

  • High-intensity statin may be considered for patients with diabetes based on additional ASCVD risk factors. 3

  • PCSK9 inhibitors like evolocumab are reserved for secondary prevention or familial hypercholesterolemia. 2, 4

  • Ezetimibe should always be tried before evolocumab due to lower cost and established safety. 2, 4

Familial Hypercholesterolemia Exception

  • Evolocumab may be considered in primary prevention only for patients with heterozygous familial hypercholesterolemia (HeFH) who are age 30-75 years with LDL-C ≥100 mg/dL despite maximally tolerated statin plus ezetimibe. 5

  • Evolocumab may be considered for HeFH patients with additional risk factors (diabetes with target organ damage, lipoprotein(a) >50 mg/dL) and LDL-C ≥140 mg/dL. 5

  • Familial hypercholesterolemia represents a special high-risk population, not true primary prevention in the general sense. 1

  • For HeFH patients without ASCVD, maximally tolerated statin plus ezetimibe therapy should be ensured before considering evolocumab. 5

Clinical Decision-Making

  • Patients with established ASCVD may be appropriate candidates for evolocumab (see secondary prevention criteria). 2

  • Patients without ASCVD and without familial hypercholesterolemia should not receive evolocumab; statins are indicated. 3, 4

  • Guidelines consistently recommend trying ezetimibe before PCSK9 inhibitors due to cost and the stepwise approach to lipid management. 2, 4, 5

  • Patients with diabetes, hypertension, or multiple risk factors without established ASCVD do not qualify for evolocumab under current guidelines. 2, 5

Safety Profile

  • Injection site reactions with evolocumab occur in <5% of patients. 1

  • Evolocumab shows no evidence of increased muscle symptoms, new-onset diabetes, hemorrhagic stroke, or neurocognitive effects. 1

  • Evolocumab is safe even at very low LDL-C levels (<20 mg/dL). 1